Diseases such as Alzheimers, dementia, sarcopenia, arthritis, Parkinsons, osteoporosis, maculopathy, COPD, and cancer increase with advancing age (Franceschi et al 2018)
Consult a qualified physician before starting any peptide protocol
Notably, those early reports touted BPC-157 as free of side effects with a very safe profile, even at high doses
From 1st week: Reduced pain (noticeable within 3-7 days) Decreased inflammation Improved range of motion Better sleep (reduced pain at night) By week 2-3: Significant pain reduction Return to light activity possible Improved tissue mobility Reduced morning stiffness Week 4-6: Major healing progress Return to normal activities for minor injuries Continued improvement for moderate injuries Tissue strength improving Week 6-8: Near complete recovery for minor injuries Significant improvement for moderate injuries Reduced risk of re-injury Can increase activity level safely Realistic expectations: BPC-157 might cut healing time by 30-50%
FOXO4-DRI is supplied as a lyophilised powder in a single sealed vial (10 mg)
Molecular basis of glutathione reductase deficiency in human blood cells